Table 1.
Baseline characteristics of all patients referred to the intensive care unit of the German Heart Centre (n = 7).
| All Patients (n = 7) | |
|---|---|
| Sex | |
| Male, n | 5 |
| Female, n | 2 |
| Age, mean (SD) | 65 (8) |
| Days of hospitalization, mean (SD) | 15 (10) |
| Death (if yes), n | 5 |
| Diabetes, n | 3 |
| Hypertension, n | 5 |
| Hypercholesterinemia, n | 3 |
| Smoking, n | 0 |
| Former Smoking, n | 1 |
| Coronary artery disease, n | 2 |
| Previous myocardial infarction, n | 1 |
| Previous CABG, n | 0 |
| Renal disease, n | 2 |
| Pulmonary disease, n | 3 |
| PCR positive, n | 6 |
| Intubated on admission, n | 7 |
| Days intubated before admission, mean (SD) | 5 (4) |
| Intubated total (days), mean (SD) | 17 (8) |
| Renal replacement therapy, n | 3 |
| Need for renal replacement therapy (days), mean (SD) | 8 (11) |
| ECMO, n | 3 |
| Need for ECMO (days), mean (SD) | 5 |
| Catecholamines, n | 6 |
| Need for Catecholamines (days), mean (SD) | 3 (3) |
| Antibiotics, n | 7 |
| Need for antibiotics (days), mean (SD) | 9 (7) |
| Thrombotic Event, n | 2 |
| Haemorrhagic Event, n | 3 |
| Arrhythmia during hospitalization, n | 5 |
| Malignant Arrhythmic Event, n | 3 |
| Pulmonary Infiltrate, n | 6 |
| Medication on admission | |
| ASS, n | 3 |
| ACE-inhibitor, n | 2 |
| AT1-antagonist, n | 2 |
| Betablocker, n | 4 |
| Diuretics, n | 2 |
| Antidiabetics, n | 3 |
| Statin, n | 3 |
| Laboratory at admission | |
| Leukocytes (103 cells/L), mean (SD) | 13 (4) |
| Hemoglobin (g/dL), mean (SD) | 10 (2) |
| Creatinine (mg/dL), mean (SD) | 3 (2) |
| GFR (mL/min/1.73), mean (SD) | 36 (26) |
| D-dimer (mg/L FEU), mean (SD) | 7 (10) |
| Troponin high-sensitive (ng/L), mean (SD) | 57 (95) |
| CK (U/L), mean (SD) | 953 (795) |
| CK-MB (U/L), mean (SD) | 48 (60) |
| CRP (mg/L), mean (SD) | 285 (127) |
| PCT (ng/L), mean (SD) | 2 (3) |
| IL-6 (ng/L), mean (SD) | 367 (231) |
| NT-proBNP (ng/L), mean (SD) | 2616 (3465) |
Abbreviations: CABG (coronary artery bypass graft), PCR (polymerase chain reaction), ECMO (extracorporeal membrane oxygenation), ASS (aspirin; acetylsalicylic acid), ACE-inhibitor (angiotensin-converting-enzyme inhibitor), AT1-antagonist (angiotensin II receptor type 1 (AT1) antagonist), GFR (glomerular filtration rate), CK (creatine kinase), CK-MB (creatine kinase muscle brain type), CRP (C-reactive protein), PCT (procalcitonin), IL-6 (Interleukin-6), NT-proBNP (N-terminal pro–braintype natriuretic peptide).